US 11,998,551 B2
Treatment of mitochondrial diseases
Ramon Martí Seves, Barcelona (ES); Emiliano González Vioque, Madrid (ES); Cora Blázquez Bermejo, Errenteria (ES); Javier Torres Torronteras, El Prat de Llobregat (ES); Raquel Cabrera Pérez, Sant Boi de Llobregat (ES); and Yolanda Cámara Navarro, Barcelona (ES)
Assigned to FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON-INSTITUT DE RECERCA, Barcelona (ES); and CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED, Madrid (ES)
Filed by FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON-INSTITUT DE RECERCA, Barcelona (ES); and CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED, Madrid (ES)
Filed on Apr. 25, 2022, as Appl. No. 17/728,698.
Application 17/728,698 is a continuation of application No. 15/578,621, granted, now 11,337,980, previously published as PCT/EP2016/062636, filed on Jun. 3, 2016.
Claims priority of application No. 15170825 (EP), filed on Jun. 5, 2015.
Prior Publication US 2023/0060544 A1, Mar. 2, 2023
Int. Cl. A61K 31/52 (2006.01); A61K 31/7068 (2006.01); A61K 31/7072 (2006.01); A61K 31/7076 (2006.01); A61K 31/708 (2006.01); A61K 45/06 (2006.01); A61P 3/00 (2006.01)
CPC A61K 31/52 (2013.01) [A61K 31/7068 (2013.01); A61K 31/7072 (2013.01); A61K 31/7076 (2013.01); A61K 31/708 (2013.01); A61K 45/06 (2013.01); A61P 3/00 (2018.01); A61K 2300/00 (2013.01)] 17 Claims
 
1. A method for the treatment of a mitochondrial DNA depletion and/or deletion syndrome due to one or more mutations in the DNA polymerase subunit gamma-1 (POLG1) protein, comprising the step of administering a therapeutically effective amount of a composition comprising deoxycytidine and deoxythymidine to a subject in need thereof, thereby treating the mitochondrial DNA depletion and/or deletion syndrome due to one or more mutations in the POLG1 protein, and wherein the deoxycytidine and deoxythymidine are present in the composition in equal amounts by weight.